Statement of Principles concerning fibrosing interstitial lung disease (Balance of Probabilities) (No. 86 of 2021)

The statutory concepts that structure this instrument are: the scope of the disease covered, a closed list of causative or aggravating factors, thresholds for quantifying exposure and timing, the evidentiary standard “balance of probabilities”, and the requirement that any factor relied upon be related to the person’s relevant service.

Scope and exclusions. Section 7(1)-(2) frames the disease: fibrosing interstitial lung disease is a group of progressive fibrosing conditions of the pulmonary interstitium. The SoP expressly excludes several specific interstitial lung pathologies (eg bronchiolitis obliterans organising pneumonia, desquamative interstitial pneumonia, hypersensitivity pneumonitis, respiratory bronchiolitis‑associated interstitial lung disease and pulmonary manifestations of systemic diseases) (s 7(2)(b)). The Schedule provides clinical notes (eg typical features) and defines related clinical terms used throughout.

Enumerated factors. Section 9 provides a closed, enumerated list of factors that, if present and shown to be related to relevant service, constitute sufficient grounds for a finding of connection on the balance of probabilities. The list groups factors by mode of causation or aggravation: tobacco smoking (pack‑years and timing), specific inhalational occupational exposures (asbestos , with separate thresholds for enclosed vs open environments , respirable crystalline silica, respirable coal dust, hard metal dust, diesel exhaust in the specified list of substances), specific toxic events (eg inhalation of mustard gas, paraquat poisoning), metal sensitising agents (beryllium), talc exposure (including intravenous use), specified medical treatments and radiation doses (eg cumulative equivalent dose of ionising radiation of at least 0.2 sievert), specific clinical syndromes (eg acute respiratory distress syndrome, acute silicosis, diffuse alveolar haemorrhage), and a list of drugs and substances defined in the Schedule (s 9; Schedule definitions).

Quantification and timing. The instrument prescribes quantitative thresholds and latency windows for many factors. Examples include: at least 20 pack‑years of smoking beginning at least 5 years before clinical onset to establish causation (subsection 9(1)); asbestos exposure for at least 1,500 cumulative hours in an enclosed space with first inhalation at least 10 years before clinical onset (subsection 9(2)); respirable crystalline silica dust for 3,000 cumulative hours with first inhalation at least 1 year before onset (subsection 9(5)); coal dust 6,000 cumulative hours with first inhalation at least 5 years before onset (subsection 9(8)). For exposure‑cessation scenarios, certain exposures require that, if exposure has ceased, onset or worsening must occur within 20 years of cessation (eg subsections 9(23)-9(24), 9(47)-9(48)).

Separation of onset and worsening. The SoP distinguishes factors sufficient to establish that the disease was incurred or materially contributed to by service (sections 9(1)-9(24)), from factors sufficient to establish that service materially contributed to clinical worsening or aggravation of a pre‑existing fibrosing interstitial lung disease (sections 9(25)-9(49)). Section 10(2) clarifies that the latter group applies only where the disease was suffered or contracted before or during, but did not arise out of, service.

Cross‑referencing and definitions. Section 11 provides that where a factor refers to another injury or disease that is the subject of another SoP, the factors of that other SoP apply in accordance with its terms. The Schedule supplies definitions that materially affect scope and thresholds, for instance “one pack‑year”, “inhaling beryllium dust or fumes” (which can include beryllium lymphocyte proliferation testing), “cumulative equivalent dose” (with a direct reference to an ARPANSA guide), and the “specified list of drugs” and “specified list of substances”. These definitional linkages import methods and standards (eg ARPANSA dose reconstruction methodology) into the instrument.

Evidentiary framing. The RMA records that the instrument is made on the basis that, on the sound medical‑scientific evidence available, it is more probable than not that the disease can be related to relevant service (s 8). The SoP is therefore an evidentiary tool for administrative determinations: it sets out factual patterns which, if established and related to service, meet the statutory causation standard used in the relevant claims provisions.

Primary individuals affected are veterans and members of the Australian Defence Forces who lodge claims under the VEA or MRCA that relate to fibrosing interstitial lung disease or to death from that disease. The instrument expressly applies to claims to which s 120B of the VEA or s 339 of the MRCA applies (s 5), so any claimant subject to those claims pathways will be affected because decision‑makers will use this SoP in assessing causation.

Decision-makers and administrators are affected. The Secretary of the Department of Veterans’ Affairs, claims assessors, and Medical Officers applying the VEA and MRCA will use this SoP as the RMA’s current medical‑scientific statement. The RMA itself is the maker of the instrument (s 3), and the Schedule imports methodologies (eg ARPANSA’s Guide to calculation of 'cumulative equivalent dose') that administrative staff or contracted experts will need to use when reconstructing radiation exposures (Schedule definition of “cumulative equivalent dose”).

Medical practitioners and expert witnesses are affected. Clinicians, occupational hygienists and forensic consultants who prepare evidence for claims must address the specific thresholds and definitions the SoP sets out: pack‑year calculations, cumulative hours in enclosed/open settings for asbestos or other dusts, the timing relationships between exposure and clinical onset or worsening, and defined clinical syndromes (eg acute respiratory distress syndrome, acute silicosis). The Schedule’s definition of “inhaling beryllium dust or fumes” explicitly admits laboratory evidence of sensitisation (beryllium lymphocyte proliferation testing) as a pathway to meet the factor (Schedule).

Employers, former employers and insurers may be indirectly affected. While the instrument does not itself impose civil liability, findings made under the VEA or MRCA about service connection can influence the scale and timing of benefits paid and the administrative record of occupational exposures. Where claims rely on workplace exposures, those exposures will be scrutinised against the SoP’s quantitative standards.

Third parties who hold exposure records are affected by evidentiary demands. Personnel records, worksite logs, asbestos removal records, maintenance logs, and radiation monitoring records become salient because many factors require cumulative hours, start dates, and cessation windows. For example, asbestos exposure thresholds differ markedly depending on whether exposure occurred in an enclosed space (1,500 cumulative hours) or an open environment (5,000 cumulative hours) (subsections 9(2)-9(3)), so records of work location and duration materially affect a claimant’s proof burden.

Families and estates are affected in death cases. The SoP defines death from fibrosing interstitial lung disease to include terminal events contributed to by the disease (s 7(3) and Schedule “terminal event”), so dependants pursuing death benefits will be affected where the disease contributed to a proximate or ultimate cause of death such as pneumonia or respiratory failure.

Finally, makers of medical records and pharmaceutical suppliers are indirectly affected because the Schedule enumerates a “specified list of drugs” (eg amiodarone, nitrofurantoin, methotrexate, tyrosine kinase inhibitors) whose recent use may qualify as a factor (Schedule). Clinicians’ documentation of drug start and stop dates, and treatment indications, will therefore be relevant.

This SoP confers no criminal duties or civil penalties by itself, but it creates administrative duties and rights in the claims context by establishing the factors that, when proven and related to relevant service, permit a finding of connection on the balance of probabilities.

Duty to apply the SoP. Decision‑makers assessing claims under the VEA or MRCA are required, as a matter of administrative law practice, to have regard to Statements of Principles produced by the RMA. The instrument is made under s 196B(3) of the VEA (s 3). While the SoP text does not set out the decision‑maker’s statutory duty in full, by its nature the SoP operates as the RMA’s medical view that must inform causation determinations in claims to which s 120B VEA or s 339 MRCA apply (s 5). Accordingly, the administrative apparatus has the duty to consider the SoP’s factors and definitions when determining whether a veteran’s disease is connected to relevant service.

Right to rely on listed factors. Claimants have the right to rely on any of the factors in section 9 as sufficient evidence of causation, provided they can prove the factor and its relationship to their relevant service (s 9 and s 10(1)). The SoP establishes that “at least one of the following factors must exist” before it can be said, on the balance of probabilities, that the disease is connected with the circumstances of relevant service (s 9 introductory text). Therefore, claimants whose exposure history or medical history meets a listed factor and who can link that factor to their relevant service have a straightforward evidentiary pathway.

Duty to show relation to relevant service. Section 10(1) requires that the existence of any factor in s 9 must be related to the person’s relevant service. The instrument therefore imposes an obligation on claimants to show that the qualifying exposure or medical event occurred in the context of relevant service as defined in the Schedule. “Relevant service” is defined to include eligible war service, defence service and peacetime service under the MRCA (Schedule definition). This creates a linkage duty: it is not sufficient to show a qualifying exposure; the exposure must be traceable to service.

Material contribution and aggravation requirements. Section 10(2) creates a substantive distinction for subsections 9(25)-9(49): those factors apply only to material contribution to, or aggravation of, fibrosing interstitial lung disease where the disease was suffered or contracted before or during relevant service but did not arise out of service. Practically, decision‑makers must determine whether the disease pre‑existed service and, if so, whether a listed factor within 9(25)-9(49) materially contributed to or aggravated the condition. This operates as a gating rule for the aggravation pathway.

Duty to apply definitions and methodologies. Several Schedule definitions import technical methodologies or tests that the decision‑maker or experts must apply. For example, “cumulative equivalent dose” directs evaluators to the ARPANSA guide in force on 2 August 2017 for dose reconstruction (Schedule). “Inhaling beryllium dust or fumes” permits demonstration by cumulative exposure (240 hours), history of acute beryllium disease, or positive beryllium lymphocyte proliferation testing (Schedule). Assessors therefore have the duty to apply those definitional standards when evaluating evidence.

Right to cross‑referenced SoPs. Section 11 provides that if a factor in this SoP refers to another injury or disease covered by a separate Statement of Principles, the factors in that other Statement apply according to its terms. Claimants and decision‑makers thereby have a right (or obligation) to move beyond this single instrument and apply the substantive content of other SoPs where relevant factors overlap.

Evidentiary standard. The RMA explicitly frames the standard underlying the SoP as “more probable than not” based on sound medical‑scientific evidence (s 8). The administrative determinations that adopt this SoP will therefore apply the balance of probabilities standard to factual findings about exposure, timing and causation.

Documentation duties for medical practitioners. Practitioners providing clinical evidence for claims will need to document the elements the SoP requires: dates (first inhalation, cessation), cumulative hours, pack‑year calculations, drug start and stop dates, diagnostic test results (eg beryllium lymphocyte proliferation), radiation dose reconstruction inputs, and clinical onset and worsening dates. The Schedule’s definition of “one pack‑year” supplies a precise calculation method that clinicians and assessors must apply.

No express penalties in the SoP. The instrument does not itself create criminal offences or civil penalties, nor does it prescribe procedures for appeal or review; these remain the province of the VEA, MRCA and their administrative processes. The SoP functions as an evidentiary standard rather than a source of standalone sanctions.

The Statement of Principles instrument does not itself create criminal offences, financial penalties, or enforcement mechanisms. It is a medical‑scientific statement made under subsection 196B(3) of the VEA (s 3) that sets out factors which, if established and linked to relevant service, constitute sufficient grounds for a finding of service connection on the balance of probabilities. The immediate legal effect is administrative: decision‑makers assessing claims under s 120B of the VEA or s 339 of the MRCA (s 5) will apply this SoP as the RMA’s current medical position on causation.

Enforcement therefore occurs through administrative decision‑making processes under the VEA and MRCA rather than via the SoP itself. A claimant whose evidence meets a listed factor and demonstrates linkage to relevant service will ordinarily obtain a favourable causation finding, which in turn may produce entitlements under the VEA or MRCA. Conversely, a failure to meet the SoP’s thresholds is a basis for a negative decision, which can be operationalised by the Department of Veterans’ Affairs in its claims processing. The instrument contains no provision for disciplinary action, sanctions, or criminal liability; any penalties for false statements, fraudulent claims, or misuse of documents would derive from other statutory provisions or general law, not from this SoP.

Monitoring and evidentiary enforcement. Practical enforcement is effected through evidentiary standards and verification processes. The SoP includes quantitative thresholds (cumulative hours, dosages, pack‑years, latency periods) and references to technical methodologies (for example the ARPANSA guide for cumulative equivalent dose). Assessors and expert witnesses will enforce those thresholds by requiring documentary proof: work records, occupational exposure logs, radiation dose records, clinical test results (eg beryllium lymphocyte proliferation tests), and medical histories. Where documentation is lacking, assessors may refuse to accept a claimed factor absent corroborating evidence; the SoP’s thresholds create an evidentiary enforcement mechanism because they are precise and verifiable.

Administrative review and appeal (contextual). The instrument does not itself prescribe appeal routes; rights of review and appeal are governed by the VEA and MRCA and their administrative mechanisms. The SoP will be a core piece of medical evidence in any such review or appeal, and tribunals or reviewing bodies will need to interpret whether a claimant’s factual evidence satisfies the SoP’s specified elements and their relationship to relevant service. The SoP’s express cross‑reference mechanism (s 11) and Schedule definitions (for technical standards) are also likely to be focal points in disputes.

Revisions and repeal. The instrument expressly repeals the prior SoP No. 54 of 2013 (s 4). Enforcement and decision‑making will therefore pivot to this updated SoP from its commencement date (s 2). Any future RMA revision or repeal will similarly change the evidentiary baseline applied by decision‑makers; this creates an institutional enforcement mechanism by which the RMA updates medical positions and thereby alters how claims are assessed.

Limitations on enforcement. The SoP does not set standards for employers, regulate workplaces, or create occupational health obligations. It is not an instrument of workplace safety enforcement; those regulatory responsibilities remain with workplace health and safety laws and regulators. The SoP operates solely for the purpose of administrative causation determinations under the specified claims provisions.

This instrument operates within the statutory framework of the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. It is made under subsection 196B(3) of the VEA (s 3) and applies to claims under s 120B of the VEA or s 339 of the MRCA (s 5). Consequently, its primary legal interaction is with the decision‑making provisions and entitlements regimes of those Acts: the SoP provides the RMA’s medical criteria for causation that must inform administrative determinations made under the VEA and MRCA.

Cross‑referencing to other Statements of Principles. Section 11 mandates that if a factor in this SoP refers to an injury or disease covered by another SoP, the factors in that other SoP apply in accordance with its terms. This creates an explicit interaction mechanism: where overlap exists (for example a factor referencing acute silicosis, paraquat poisoning, or another disease that is separately the subject of a SoP), adjudicators must consult and apply the relevant other SoP content as well as this instrument. The cross‑reference aligns the RMA’s suite of SoPs into an interlocking evidentiary framework.

Interaction with diagnostic and dose‑reconstruction methodologies. The Schedule’s definition of “cumulative equivalent dose” incorporates the ARPANSA Guide to calculation of 'cumulative equivalent dose' (as in force on 2 August 2017). That reference legalises the incorporation of ARPANSA’s technical methodology into administrative determinations under the VEA and MRCA. In practice, dose reconstruction performed for claims will follow ARPANSA methodology and the results will be assessed against the threshold in subsection 9(13) and comparable provisions for clinical worsening.

Relationship to workplace and public health law. The SoP does not displace or modify occupational health and safety obligations, workers’ compensation schemes, or environmental regulation; it is an administrative evidence instrument for veterans’ entitlements. However, findings made under the SoP can intersect evidence generated under workplace or regulatory processes. For example, workplace exposure records created for Work Health and Safety compliance or workers’ compensation claims will be relevant evidence in a SoP‑based assessment. The instrument does not create duties for employers or regulators, nor does it constrain them: its function is evidentiary within the VEA/MRCA context.

Overlap with civil liability. The SoP itself does not create or extinguish civil rights or liabilities. Findings made in the context of an entitlement decision may nevertheless inform civil claims by providing an evidentiary base for causation, but the instrument does not bind civil courts and does not set civil liability rules. Section 11’s cross‑references to other SoPs may bring into play medical standards that civil litigants can use as evidence, but any legal effect in civil proceedings depends on the court’s assessment of admissibility and probative value, not on the SoP alone.

Temporal interaction with earlier and future SoPs. The instrument expressly repeals the 2013 SoP (s 4). That repeal changes the operative RMA medical position from the commencement date (s 2). Future updates by the RMA will similarly change the evidentiary baseline for claims, and section 11 ensures that content of other SoPs interacts by reference. The RMA’s framings therefore evolve the administrative law landscape over time, and decision‑makers must apply the SoP in force at the relevant decision date.

Interaction with medical practice and standards. The SoP brings into administrative decision‑making certain clinical definitions that align with accepted medical practice (for example the Schedule definitions of acute respiratory distress syndrome, diffuse alveolar haemorrhage, exogenous lipoid pneumonitis). The RMA’s statement that it acted on “sound medical‑scientific evidence” (s 8) ties the SoP into clinical standards and tests. This interaction requires that medical experts and treating practitioners provide evidence in terms consistent with the SoP’s definitions and thresholds.

Procedural law interaction. The instrument does not itself set procedural rights such as appeal pathways; these are set out in the VEA and MRCA. Nevertheless, the SoP’s content will be central to procedural challenges to causation decisions where claimants seek merits review or judicial review under the procedural regimes of the relevant Acts.

This instrument’s amendment history, as recorded within the text, is succinct. The current Statement of Principles concerning fibrosing interstitial lung disease (No. 86 of 2021) is dated 20 August 2021 and commenced on 20 September 2021 (s 2 and the heading). Section 4 expressly repeals the previous Statement of Principles concerning fibrosing interstitial lung disease No. 54 of 2013 (Federal Register of Legislation No. F2013L01642), which had been made under subsections 196B(3) and (8) of the VEA. The repeal transfers the operative RMA position from the 2013 instrument to the 2021 instrument as at commencement.

There are no further amendments recorded within the instrument itself. The Schedule refers to external materials where the version is fixed at a particular date for the purposes of the instrument: the “cumulative equivalent dose” definition directs users to the ARPANSA Guide in force on 2 August 2017. That is an explicit lock‑in of one external technical reference as of that ARPANSA version. Any subsequent changes to the ARPANSA Guide are not automatically incorporated by the instrument; decision‑makers are directed to the guide as it was on the specified date.

Because the instrument is an RMA SoP under the VEA, any future changes would be effected by the RMA issuing a new or amended SoP under the relevant powers in the VEA. The instrument contains no sunset clause, staged amendments, or transitional rules within its text. The only internal historical note is the replacement of the 2013 document.

Practically, this means that decision‑makers must apply the 2021 SoP to claims determined after its commencement unless transitional provisions in the VEA, MRCA, or other administrative guidance specify otherwise. The instrument does not itself set an explicit transitional regime for claims lodged before commencement; administrators will need to consult the VEA/MRCA and departmental policy for transitional handling. The repeal of the 2013 SoP (s 4) indicates the RMA intended the 2021 instrument to replace and update the medical criteria used in causation determinations.

No other amendments, revocations, or subsequent revisions are recorded in the text provided. Any practitioners or claimants seeking to know whether a later SoP has superseded the 2021 instrument must check the Federal Register of Legislation and the RMA’s publications for newer Statements of Principles issued after the date of this instrument.

This Statement of Principles instrument itself does not record any litigation history. There are no cases or tribunal decisions cited within the text, and the instrument does not purport to summarise judicial, tribunal, or administrative decisions concerning its content. The sole procedural history item the instrument records is the repeal of the previous 2013 SoP (s 4).

Because the instrument functions as an evidentiary and administrative tool for use under the VEA and MRCA (s 5), it is likely to feature in merits review or judicial review proceedings concerning individual claims under those Acts. However, the instrument contains no internal account of such proceedings, and it names no cases. The Schedule references authoritative technical material (the ARPANSA guide) but not litigated interpretations.

For practitioners researching litigation trends, the absence of litigation history in the SoP means that any judicial or tribunal engagement with its content must be sought from external databases: court or tribunal decisions, Veterans' Review Board determinations, Administrative Appeals Tribunal decisions, and judicial reviews where claimants have challenged adverse decisions that relied on SoP application. The instrument’s text does not provide guidance on how courts or tribunals have treated the SoP, nor does it state whether its contents are conclusive evidence of causation in other fora. The RMA’s SoPs are generally an important component of administrative reasoning; whether they are dispositive in any given proceeding depends on statutory interpretation and the tribunal or court’s assessment of probative value.

In short, the instrument contains no internal litigation history to report. Any litigation history relevant to this SoP must be derived from external reporting of decisions made under the VEA and MRCA that engage the SoP’s content after its commencement on 20 September 2021.

The instrument contains numerous technical thresholds, cross‑references and definitional choices that create practical pitfalls for claimants and advisers. These “gotchas” are grounded in the text and can be decisive in whether a claim succeeds.

1. Distinction between onset and worsening. The SoP separates factors that establish the disease was caused by service (subsections 9(1)-9(24)) from factors that establish material contribution to, or aggravation of, an already existing disease (subsections 9(25)-9(49)). Section 10(2) limits the latter group to cases where the disease was suffered or contracted before or during, but did not arise out of, service. A claimant whose disease first arose out of service cannot rely on subsections 9(25)-9(49) to prove causation; they must fit a factor in 9(1)-9(24). Misstating onset dates or failing to establish pre‑service disease can therefore defeat a claim that relies on the aggravation factors.

2. Quantitative thresholds and latency requirements. Many factors have precise cumulative‑hours or dose thresholds and minimum latency periods. For example, asbestos exposure in an enclosed space requires 1,500 cumulative hours and the first inhalation to have commenced at least 10 years before clinical onset (subsection 9(2)); silica requires 3,000 cumulative hours with first inhalation at least 1 year before onset (subsection 9(5)); coal dust 6,000 hours with a 5‑year first inhalation latency (subsection 9(8)). Similarly, smoking requires 20 pack‑years and commencement at least 5 years before clinical onset to qualify for causation (subsection 9(1)), whereas only 10 pack‑years and a 1‑year commencement are required to establish clinical worsening (subsection 9(25)). Small differences in dates or cumulative exposure calculations can therefore change an outcome.

3. Enclosed versus open environment. For asbestos and other vapour/gas/dust/fume exposures, thresholds differ depending on whether exposure occurred in an enclosed space or open environment (subsections 9(2)-9(3), 9(23)-9(24), 9(26), 9(47)-9(48)). Accurate proof of the worksite setting and documentation of hours spent in those environments matters. Records that simply identify tasks without specifying setting can be insufficient.

4. Exposure cessation windows. Several factors that require cumulative exposure specify that if exposure has ceased, onset or worsening must have occurred within 20 years of cessation (subsections 9(23)-9(24), 9(47)-9(48)). A claimant who ceased exposure more than 20 years before onset or worsening may fail even if cumulative hours otherwise meet the threshold.

5. Defined technical methodologies. The Schedule imports ARPANSA’s guide for dose reconstruction for ionising radiation (Schedule). If radiation exposure evidence is required, claimants must provide inputs suitable for ARPANSA methodology; ad hoc dose estimates may be rejected.

6. “Inhaling beryllium dust or fumes” permits three alternative proofs, including positive beryllium lymphocyte proliferation testing (Schedule). Claimants who cannot meet the 240 cumulative‑hour exposure threshold might nevertheless meet the criterion by laboratory evidence of sensitisation; absence of such tests can be fatal to proof.

7. The “specified list of drugs” and “specified list of substances” are closed lists in the Schedule. If a claimant took a drug that is not on the specified list, it will not qualify under the corresponding factors (for onset or worsening). Advisers must check the Schedule to see whether a drug or substance is included.

8. Exclusions in scope. The SoP expressly excludes certain interstitial lung diseases from its scope (s 7(2)(b)). A claimant diagnosed with one of the excluded conditions (eg hypersensitivity pneumonitis) cannot rely on this instrument to prove causation; separate SoPs or legal routes must be considered.

9. “Death” includes terminal events contributed to by the disease. Section 7(3) and the Schedule’s definition of “terminal event” mean that death certificates showing pneumonia or respiratory failure may be linked to an underlying fibrosing interstitial lung disease if medical evidence shows the disease contributed to the terminal event. However, establishing contribution requires medical evidence connecting the disease to the terminal event; the SoP does not make contribution automatic.

10. “Inability to obtain appropriate clinical management” as a factor (subsection 9(49)). This is a non‑exposure factor that can be relevant to clinical worsening. However, s 10(2) restricts worsening factors to cases where disease preceded or began during service. Documentation of what constituted “appropriate clinical management”, the time periods involved, and causal connection to worsening will be scrutinised.

11. Differences in time windows for therapeutic exposures. Several therapeutic exposures have specific minimum periods before they can be considered causative: therapeutic radiation with affected lung in the field requires at least 6 months before onset (subsections 9(14) and 9(37)); iodine‑131 for pulmonary metastases requires at least 6 months (subsections 9(15) and 9(38)); yttrium‑90 microspheres require at least 3 months (subsections 9(16) and 9(39)). Precise treatment dates therefore matter.

12. Acute inhalational injury requirements. To meet the toxic gas/fumes acute exposure factor (subsections 9(10) and 9(33)), there must have been severe acute lower respiratory damage requiring medical attention within 48 hours and persistence of respiratory signs and symptoms for at least 1 week after exposure, within the 1 year before onset or worsening. Casual reports of smoke exposure without contemporaneous medical attention and objective notes will often fail.

13. Proof of pack‑years. The Schedule defines “one pack‑year” precisely, including equivalence to grams of tobacco, and provides examples for calculation. Advisers must ensure pack‑year calculations and supporting evidence match the Schedule’s method.

14. Cross‑SoP referral. If a factor refers to another disease for which a separate SoP exists, the other SoP applies (s 11). Failure to identify such cross‑references can result in incomplete arguments.

Each of these textual features means that success often turns on precise documentary proof, accurate date‑stamping, and the selection of the correct pathway (onset vs aggravation). Advisers must map clinical histories to the specific subsections and Schedule definitions to avoid avoidable failures.

Compliance, in the context of this SoP, means preparing and presenting evidence that aligns with the instrument’s precise factual and technical requirements so that a decision‑maker can conclude, on the balance of probabilities, that at least one listed factor existed and was related to the person’s relevant service (ss 9 and 10).

1. Map the claim to onset or worsening. Determine whether the claim asserts that fibrosing interstitial lung disease was first incurred as a result of service (use subsections 9(1)-9(24)) or that service materially contributed to clinical worsening of a pre‑existing disease (use subsections 9(25)-9(49)). Apply s 10(2) to confirm whether the worsening pathway is available (disease must have been suffered or contracted before or during, but not arising out of, service).

2. Establish relevant service. Document the nature of the person’s relevant service as defined in the Schedule: eligible war service, defence service, or peacetime service under the MRCA. Provide service records, postings, role descriptions, and any deployment information that ties the exposure or event to service.

3. Evidence matching the specific subsection. For each factor relied upon, gather the precise evidence the subsection requires:

   • Pack‑years: calculate according to the Schedule’s “one pack‑year” definition, supply contemporaneous records, GP notes, smoking histories, and corroborating statements (Schedule).
   • Cumulative hours: for asbestos, silica, coal, hard metal, or specified substances, compile work rosters, task logs, contractor records, site entry/exit logs, maintenance schedules and colleague statements to substantiate cumulative hours and whether exposure occurred in an enclosed or open environment (subsections 9(2)-9(3), 9(5), 9(8), 9(9), 9(23)-9(24), 9(47)-9(48)).
   • Acute inhalation events: supply contemporaneous medical records showing presentation within 48 hours, treatment, and persistence of symptoms for at least 1 week (subsections 9(10) and 9(33)).
   • Beryllium: provide exposure histories, evidence of cumulative exposure where available, records of any acute beryllium disease, and results of beryllium lymphocyte proliferation tests where performed (Schedule).
   • Radiation: assemble dosimetry records, medical radiation procedure reports, and inputs for ARPANSA dose reconstruction; ensure dose calculations follow the ARPANSA guide referenced in the Schedule (subsection 9(13); Schedule).
   • Drugs and therapeutic agents: document prescriptions, start/stop dates, indications, and proximity to clinical onset or worsening for drugs on the “specified list of drugs” (Schedule and subsections 9(19) and 9(42)).
   • Clinical syndromes: provide diagnostic reports, imaging, pulmonary function testing, histopathology, and specialist letters to establish diagnoses such as acute respiratory distress syndrome, acute silicosis, diffuse alveolar haemorrhage, exogenous lipoid pneumonitis or tropical pulmonary eosinophilia (subsections 9(6), 9(16), 9(17), 9(20)-9(22), and Schedule).

4. Date stamping and latency. Establish dates for first exposure, cumulative exposure windows, treatment dates, onset of symptoms, and dates of clinical worsening. Compare those dates to the latency and timing thresholds in each relevant subsection (for example minimum 10‑year latency for asbestos first inhalation in s 9(2), 1 year for silica in s 9(5), 5 years for coal in s 9(8)).

5. Address cessation windows. If exposure ceased prior to onset or worsening, document cessation dates and ensure onset/worsening dates fall within the 20‑year windows where specified (subsections 9(23)-9(24), 9(47)-9(48)).

6. Use appropriate experts and methodologies. Where technical reconstruction is required (eg cumulative equivalent radiation dose), use experts familiar with the ARPANSA guide referenced in the Schedule so the inputs and methods align with the SoP’s incorporated standard. For occupational exposure quantification, engage occupational hygienists to produce cumulative‑hour estimates based on documented work histories.

7. Cross‑referenced SoPs and excluded conditions. Check whether any factor references another SoP (s 11) and obtain or prepare evidence accordingly. Also verify the person’s specific diagnosis against the exclusions in s 7(2)(b) so that the correct SoP is being used; if the diagnosed condition is excluded, seek the appropriate separate SoP or legal pathway.

8. Address inability to obtain appropriate clinical management. If relying on subsection 9(49), document clinical management attempts, access barriers, timelines and how lack of management materially contributed to worsening. This requires contemporaneous clinical notes, referral attempts, waitlists, or system‑level constraints.

9. Collate corroborative third‑party documents. Secure service records, employer records, statutory declarations from colleagues, asbestos removal or site reports, radiation dosimetry and treatment records, pharmacy dispensing records, and hospital notes. The SoP’s quantitative thresholds make documentary corroboration particularly important.

10. Present causation in SoP terms. Frame medico‑legal reports and submissions in the terminology and subsection format of the SoP: state which subsection(s) of s 9 are relied upon, specify how each element of that subsection is met by the evidence (hours, dates, tests), and explain the link to relevant service per s 10(1).

11. Anticipate alternative explanations and exclusions. Prepare to rebut competing aetiologies (eg excluded conditions listed in s 7(2)(b)) with differential diagnosis and expert evidence showing why the claimed factor, rather than an excluded disease or unrelated exposure, is the more probable cause.

12. Keep records for review. Because SoPs are applied in administrative decision‑making and potentially in review proceedings, maintain comprehensive records of evidence gathering, expert instructions, and method statements for dose reconstruction and exposure assessment.

Following these steps aligns evidence and procedural practice with the SoP’s precise requirements and reduces the risk that a claim fails due to mismatches between the facts and the instrument’s detailed thresholds and definitions.